Portal de investigación
Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Munoz-Aceituno, E
- Butrón-Bris, B
- Ovejero-Benito, MC
- Rodríguez, OB
- Herrera-Acosta, E
- Rivera-Diaz, R
- Ferran, M
- Sanchez-Carazo, JL
- Riera-Monroig, J
- Pujol-Montcusí, J
- Vidal, D
- de la Cueva, P
- García-Bustinduy, M
- Ruiz-Villaverde, R
- Ballescà, F
- Llamas-Velasco, M
- Navares, M
- Palomar-Moreno, I
- Sanchez-García, I
- Garcia-Martínez, J
- Novalbos, J
- Zubiaur, P
- Abad-Santos, F
- Daudén-Tello, E
- de la Fuente, H
Grupos
Abstract
BackgroundPrediction of the response to a biological treatment in psoriasis patients would allow efficient treatment allocation.ObjectiveTo identify polymorphisms associated with secukinumab response in psoriasis patients in a daily practice setting.MethodsWe studied 180 SNPs in patients with moderate-to-severe plaque psoriasis recruited from 15 Spanish hospitals. Treatment effectiveness was evaluated by absolute PASI <= 3 and <= 1 at 6 and 12 months. Individuals were genotyped using a custom Taqman array. Multiple logistic regression models were generated. Sensitivity, specificity and area under the curve (AUC) were analysed.ResultsA total of 173 patients were studied at 6 months, (67% achieved absolute PASI <= 3 and 65% PASI <= 1) and 162 at 12 months (75% achieved absolute PASI <= 3 and 64% PASI <= 1). Multivariable analysis showed the association of different sets of SNPs with the response to secukinumab. The model of absolute PASI <= 3 at 6 months showed best values of sensitivity and specificity. Four SNPs were associated with the capability of achieving absolute PASI <= 3 at 6 months. rs1801274 (FCGR2A), rs2431697 (miR-146a) and rs10484554 (HLCw6) were identified as risk factors for failure to achieve absolute PASI <= 3, while rs1051738 (PDE4A) was protective. AUC including these genotypes, weight of patients and history of biological therapy was 0.88 (95% CI 0.83-0.94), with a sensitivity of 48.6% and specificity of 95.7% to discriminate between both phenotypes.ConclusionWe have identified a series of polymorphisms associated with the response to secukinumab capable of predicting the potential response/non-response to this drug in patients with plaque psoriasis.
© 2024 European Academy of Dermatology and Venereology.
Datos de la publicación
- ISSN/ISSNe:
- 0926-9959, 1468-3083
- Tipo:
- Article
- Páginas:
- 1783-1790
- DOI:
- 10.1111/jdv.19782
- PubMed:
- 38153843
- Factor de Impacto:
- 1,613 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY WILEY
Citas Recibidas en Web of Science: 8
Documentos
- No hay documentos
Filiaciones
Cita
Munoz E,Butrón B,Ovejero MC,SAHUQUILLO A,Rodríguez OB,Herrera E,Rivera R,Ferran M,Sanchez JL,Riera J,Pujol J,Vidal D,de la Cueva P,García M,Ruiz R,Ballescà F,Llamas M,Navares M,Palomar I,Sanchez I,Garcia J,Novalbos J,Zubiaur P,Abad F,Daudén E,de la Fuente H. Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice. J. Eur. Acad. Dermatol. Venereol. 2024. 38. (9):p. 1783-1790. IF:8,000. (1).